Authors
Latest:
How Physicians Can Detect ctDNA in MelanomaDavid Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.
Latest:
Gandara Reviews Chemotherapy and Immunotherapy for NSCLC Based on StageAn otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was was later diagnosed with NSCLC.
Latest:
Interim Analysis Demonstrates Reassuring Toxicity Profile for GlioblastomaDavid Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
Latest:
Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast CancerDavid Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br />
Latest:
Hong Discusses Patients Who Benefit From LarotrectinibDavid S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.
Latest:
The Impact of Neuroendocrine Tumor Heterogeneity During Disease ProgressionDavid S. Klimstra, MD, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, at the 2014 NANETS Symposium.
Latest:
Ruxolitinib Used to Prevent GVHD Throughout Stem Cell TransplantationDavid S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.
Latest:
Phase Ib/II Results for TP53-Mutant MDS and AMLDavid Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Latest:
Fostering Excellence in Care and Outcomes in Patients With Stage III and IV NSCLCDavid Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, director of the Lung cancer Research Program, and member of the Association of Community Cancer Centers explains to <em>Targeted Oncology, </em>the ways in which ACCC is improving the care landscape and outcomes for patients with advanced non–small cell lung cancer.
Latest:
Dr. David Steensma on Midostaurin and its Future Uses in Acute LeukemiaDavid Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Latest:
Genomic Features of SarcomaDavid Thomas, FRACP, PhD, director and division head, Genomic Cancer Medicine, Cancer Division, Garvan Institute of Medical Research, discusses the genomic features of sarcoma and how they factor into the treatment landscape of this disease.
Latest:
Chemotherapy-Induced Peripheral Neuropathy in Breast CancerDawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
Latest:
The Changing Landscape of Oncology: Impact for Payers and ProvidersCancer strikes fear as a clinical diagnosis. It also keeps employer medical directors up at night, wondering what the future will bring in the context of the limited dollars available for all medical care and diseases.
Latest:
The Future of Surgery and Targeted TherapiesDeanna J. Attai, MD, discusses the future of surgery and targeted therapies in the treatment of breast cancer.
Latest:
New Metastatic Cervical Cancer Treatments Give HopeInvestigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.
Latest:
Unique Combinations to Optimize CAR T-Cell Therapy in Hematologic MalignanciesResearchers are working to optimize the outcomes associated with CAR T-cell therapy, focusing on unique combinations that may enhance T-cell fitness, improving tumor eradication and treatment outcomes.
Latest:
Using Digital Health to Promote Equity in Community Oncology PracticesDebra A. Patt, MD, PhD, MBA, discusses a study of digital health systems used at Texas Oncology locations and how it helps with remote communication between patients with cancer and clinicians.
Latest:
Immunotherapy May Lead to Abnormal Thyroid Function in Patients With CancerA comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.
Latest:
Japanese Clinical Trial Aims to Standardize Anaplastic Thyroid Carcinoma TreatmentA Japanese research team attempted to standardize therapy for anaplastic thyroid carcinoma by assessing the feasibility and efficacy of weekly paclitaxel administration.
Latest:
Tripathy Provides an Overview of the TBCRC049 Study for HER2+ Breast CancerDebu Tripathy, MD, discusses the TBCRC049 study which evaluated tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Latest:
Adapting to the New Value-Based Payment ModelsDeepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.
Latest:
Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory MyelomaDeepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs and Future Treatment Approaches in Gastric CancerDeidre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses unmet needs as well as future treatment approaches for patients with gastric cancer.
Latest:
Dr. Deirdre Cohen on When to Treat Gastric Cancer Patients With ImmunotherapiesDr. Deirdre Cohen talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers.
Latest:
The Treatment of Patients With Bone Health IssuesDenise A. Yardley, MD, senior investigator, Sarah Cannon Research Institute, on the treatment of patients with breast cancer with bone health issues.
